ATLANTA, March 02, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will present a corporate overview at the Q1 Investor Summit Conference, which is being held virtually on March 8 – 9, 2022.
Mr. Eiswirth will deliver his corporate presentation on Wednesday, March 9, 2022 at 8:45 AM ET.
Additionally, Mr. Eiswirth and Phil Jones, Alimera’s Chief Financial Officer, will be available for one-on-one investor meetings on Wednesday, March 9, 2022.
Click here to register: Q1 Investor Summit – INVESTOR REGISTRATION
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com |
For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…